Sept. 14, 2007- Exelixis, Inc. (Nasdaq: EXEL) announced that the company has submitted a comprehensive data report relating to XL880 to GlaxoSmithKline (GSK)...
XL880 has attractive pharmaceutical properties, with high solubility and oral bioavailability. In preclinical studies, XL880 inhibited its targets with nanomolar potency, and retained potent activity against mutationally activated forms of MET found in hereditary papillary renal cell carcinomas. The compound also demonstrated dose-dependent tumor growth inhibition in models of breast cancer, colorectal cancer, non-small cell lung cancer, and glioblastoma, and has been shown to cause substantial tumor regression in all models tested...
